HC Wainwright & Co. Downgrades Cyclo Therapeutics to Neutral, Lowers Price Target to $0.95
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has downgraded Cyclo Therapeutics from Buy to Neutral and reduced the price target from $3 to $0.95, indicating a less optimistic outlook for the company's stock.
August 23, 2024 | 11:23 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
HC Wainwright & Co. has downgraded Cyclo Therapeutics from Buy to Neutral and lowered the price target from $3 to $0.95, suggesting a less favorable view on the stock's potential.
The downgrade from Buy to Neutral and the significant reduction in the price target from $3 to $0.95 by HC Wainwright & Co. indicates a negative reassessment of Cyclo Therapeutics' stock potential. This is likely to lead to a short-term decline in the stock price as investors adjust to the new outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100